(2026). Reducing breast cancer recurrences with CDK4/6 inhibitor treatment of HR-positive, HER2-negative early stage breast cancer from a societal perspective. Health Economics Review.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Reducing Breast Cancer Recurrences with CDK4/6 Inhibitor Treatment of HR-positive, HER2-negative Early Stage Breast Cancer from a Societal Perspective."
Health Economics Review 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Reducing Breast Cancer Recurrences with CDK4/6 Inhibitor Treatment of HR-positive, HER2-negative Early Stage Breast Cancer from a Societal Perspective."
Health Economics Review, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.